Equity Profile

OGN

Organon & Co.

Health CarePharmaceuticals$3.6B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating profit.

$1.07

Revenue

Total revenue is crucial for understanding the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health needs. With a market cap of $4 billion, it plays a vital role in providing essential medications and treatments in the healthcare sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1 2026, Organon reported an EPS of $0.71, falling short of the expected $0.81, marking a 12.88% surprise to the downside. The stock reacted negatively, declining by 0.67% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Organon to report an EPS of $1.07 and revenue of $1.6 billion for Q2 2026, indicating a cautious outlook following recent earnings misses.

Bull Case

If Organon can exceed EPS expectations and show strong revenue growth, it may signal a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its ability to manage costs and maintain market share, leading to further declines in stock price.

Key Metrics to Watch

EPS

$1.07

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating profit.

Revenue

$1.6B

Total revenue is crucial for understanding the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Organon achieve an EPS of at least $1.07?

This specific EPS target is crucial for restoring investor confidence after recent misses.

What revenue figures will Organon report, and how do they compare to the $1.6 billion consensus?

Revenue performance will indicate market demand for Organon's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for a rebound in demand for Organon's products, particularly in women's health, which could drive better-than-expected results.

Supporting Evidence

The company's recent product launches may not be fully reflected in current revenue expectations.

Options pricing suggests a significant move, indicating that traders are anticipating a larger shift than the consensus suggests.

Key Risk

If Organon reports strong demand in key product lines, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a trend of earnings misses, and investors are looking for signs of recovery.

Bull Confirmed If

Exceeding $1.07 EPS and reporting revenue above $1.6 billion would confirm a positive outlook.

Bear Confirmed If

Falling short of the $1.07 EPS and $1.6 billion revenue targets would reinforce concerns about the company's growth.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors await further clarity on future growth prospects.

Miss

A miss could result in a decline, with historical data indicating an average drop of around 4.43% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand trends for women's health products.
4Guidance on future earnings and revenue expectations.
5Responses to analyst questions regarding competitive pressures in the pharmaceutical sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other critical health needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating profit.

$1.07

Revenue

Total revenue is crucial for understanding the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In Q1 2026, Organon reported an EPS of $0.71, falling short of the expected $0.81, marking a 12.88% surprise to the downside. The stock reacted negatively, declining by 0.67% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Organon to report an EPS of $1.07 and revenue of $1.6 billion for Q2 2026, indicating a cautious outlook following recent earnings misses.

Bull Case

If Organon can exceed EPS expectations and show strong revenue growth, it may signal a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its ability to manage costs and maintain market share, leading to further declines in stock price.

Key Metrics to Watch

EPS

$1.07

Earnings per share is a key indicator of profitability and will help gauge how well the company is managing its costs and generating profit.

Revenue

$1.6B

Total revenue is crucial for understanding the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Organon achieve an EPS of at least $1.07?

This specific EPS target is crucial for restoring investor confidence after recent misses.

What revenue figures will Organon report, and how do they compare to the $1.6 billion consensus?

Revenue performance will indicate market demand for Organon's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for a rebound in demand for Organon's products, particularly in women's health, which could drive better-than-expected results.

Supporting Evidence

The company's recent product launches may not be fully reflected in current revenue expectations.

Options pricing suggests a significant move, indicating that traders are anticipating a larger shift than the consensus suggests.

Key Risk

If Organon reports strong demand in key product lines, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a trend of earnings misses, and investors are looking for signs of recovery.

Bull Confirmed If

Exceeding $1.07 EPS and reporting revenue above $1.6 billion would confirm a positive outlook.

Bear Confirmed If

Falling short of the $1.07 EPS and $1.6 billion revenue targets would reinforce concerns about the company's growth.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors await further clarity on future growth prospects.

Miss

A miss could result in a decline, with historical data indicating an average drop of around 4.43% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand trends for women's health products.
4Guidance on future earnings and revenue expectations.
5Responses to analyst questions regarding competitive pressures in the pharmaceutical sector.